Login | New Member? Signup Free
ChangeDetect » News

USPTO issues patent to Rexahn’s new anti-cancer arylisoquinolinamine compounds

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the United States Patent & Trademark Office has issued U.S. Patent No. 8,034,829 to Rexahn, entitled “5, 6, or 7-Substituted-3- arylisoquinolinamine derivatives and therapeutic use thereof.”

Tags: , , , , , , , , , , , ,